Course
Pharmaceutical Regulation and Registration Procedures in Japan
- 18 April 2024
- Zoom
- 5 hours
- English
- 16:00-21:00 Brussels
- 15:00-20:00 UK
- 10:00am-03:00pm New York
$700
Until 23 Mar 2024
$780
Until 11 Apr 2024
$900
Until 18 Apr 2024
Lecturer: Dror Wohlfeiler
Dr. Dror Wohlfeiler is a seasoned pharmaceutical professional with more than 30 years of experience gained working in the EU, US, Israel, Japan and other Asian countries, in site, regional and corporate roles.
Headed the Japan specialty and generic R&D project development at Teva from 2007 to 2017. Before 2007 acted as head of Quality Control for Teva’s operation division.
Built and managed teams in branded and generic R&D, supervised global project teams for Phase I - III drug developments resulting in more than 100 approved ANDA submissions, 2 NDA’s and numerous Phase 3 trials in Japan.
Used to work and live for 4 years in Japan started at t Kowa-Teva JV as the head o
Headed the Japan specialty and generic R&D project development at Teva from 2007 to 2017. Before 2007 acted as head of Quality Control for Teva’s operation division.
Built and managed teams in branded and generic R&D, supervised global project teams for Phase I - III drug developments resulting in more than 100 approved ANDA submissions, 2 NDA’s and numerous Phase 3 trials in Japan.
Used to work and live for 4 years in Japan started at t Kowa-Teva JV as the head o
THE REGULATORY AFFAIR ENVIRONMENT IN JAPAN
Understand how to successfully navigate the Japanese health authorities and bring pharmaceutical products into the Japanese market.
This course will provide:
- A thorough overview and in-depth case studies on how to successfully navigate the Japanese health authorities and bring pharmaceutical products onto the Japanese market.
- The do’s and don’ts of constructive interactions with Japanese colleagues and officials
- The participant will become familiar with the contents of drug files, and the Japanese regulatory system, including the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labor and Welfare (MHLW).
- The regulatory procedures will be discussed throughout the drug development phases and how to successfully consult with PMDA, e.g, in the clinical trial notification phase.
- You will get the latest trends in Japanese pharmaceutical regulations and procedures.
- Understand the Japanese drug development and post-approval framework and regulatory procedure in CMC, clinical and regulatory audits.
- The company will be benefited from an employee who understands the Japanese drug development, post-approval framework and regulatory procedures and a regulatory professional who can make recommendations on how to achieve project goals in the shortest possible development time
- A regulatory professional who can play an important strategic role in project teams working on obtaining a marketing authorization in Japan